- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Venetoclax, as a BCL-2 inhibitor, commonly has side effects such as bone marrow suppression, gastrointestinal reactions, and tumor lysis syndro...
Venetoclax, as a BCL-2 inhibitor, needs to be adjusted according to physiological status and organ function when used in special populations. T...
The use of Infiglatinib in special populations needs to be adjusted based on pregnancy, lactation, liver and kidney function, and strict risk a...
Infiglatinib, as an FGFR inhibitor, commonly has side effects such as eye, skin, and electrolyte imbalances. Targeted monitoring and interventi...
The side effects of Ixazomib include blood system abnormalities, gastrointestinal reactions, peripheral neuropathy, etc., which need to be al...
Ixazomib, as a proteasome inhibitor, varies in efficacy depending on individual differences. It usually requires continuous medication for 2-4 ...
Lazertinib, as a targeted therapy drug, has side effects that include multiple systemic manifestations such as skin reactions and venous thro...
Lazertinib is an oral third-generation EGFR tyrosine kinase inhibitor mainly used for the treatment of EGFR mutant non-small cell lung cancer. ...
Pemigatinib is an FGFR inhibitor mainly used to treat malignant tumors such as cholangiocarcinoma. Its common side effects include hyperphospha...
The use of Pemigatinib in special populations needs to be adjusted according to pregnancy, lactation, liver and kidney function, and other fact...
